US Patent

US11033626 — Progesterone formulations having a desirable pk profile

Method of Use · Assigned to TherapeuticsMD Inc · Expires 2032-11-21 · 7y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects progesterone formulations that allow for a reduction in the amount of progesterone administered to a patient.

USPTO Abstract

This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.

Drugs covered by this patent

Estrace (ESTRADIOL) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2439`	—	Estrace
`U-2439`	—	Estrace

Patent Metadata

Patent number: US11033626
Jurisdiction: US
Classification: Method of Use
Expires: 2032-11-21
Drug substance claim: No
Drug product claim: Yes
Assignee: TherapeuticsMD Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.